Clinical Study
Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
Table 3
Demographic data Stage IIIA versus Stage IIIC epithelial ovarian cancer, US SEER 18 Registries 2000–2009.
| | Stage | IIIA | IIIC | Significance |
| | Number | 794 | 11,967 | | | Age at diagnosis (mean) | | | |
| | | | | |
| | Race | | | | | Black | 49 (6.2%) | 712 (5.9%) | | | White | 680 (85.6%) | 10,456 (87.4%) | | Other | 65 (8.2%) | 799 (6.7%) | | Appalachian Region | | | | | Appalachia | 30 (3.8%) | 539 (4.5%) | | | Non-Appalachia | 764 (96.2%) | 11,428 (95.5%) | | Urban region | | | | | Rural | 78 (9.8%) | 1,199 (10.0%) | | | Urban | 716 (90.2%) | 10,768 (90.0%) | | Cell type | | | | | Serous carcinoma | 396 (50.0%) | 7,952 (66.4%) | | | Endometrioid carcinoma | 90 (11.3%) | 740 (6.2%) | | Mixed adenocarcinoma (NOS) | 32 (4.0%) | 437 (3.7%) | | Mucinous carcinoma | 91 (11.5%) | 1,282 (10.7%) | | Carcinoma (NOS), other | 185 (23.2%) | 1,556 (13.0%) |
|
|
NOS: not otherwise specified.
|
